Barely Significant
← all excerpts

Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults-Results From an Early-Stage Clinical Trial.

Diabetes Metab Res Rev · 2025 · PMC12126752 · PMID 40450548

Europe PMCDOI
1
hedged sentence
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

a notable trendp = 0.07so close (0.05 < p ≤ 0.1)
However, in the subset of subjects not taking antihypertensive medication (5 of 8 in the placebo group, 3 of 7 in the 2 mg Pep19 group, and 6 of 8 in the 5 mg Pep19 group) after 60 days, there was a notable trend towards decreased systolic blood pressure in the 5 mg Pep19 group compared to placebo ( p = 0.07), and also compared to baseline ( p = 0.08) (Table 4 and Figure 3 ). 3.5 Visceral Fat and Lean Mass Assessments Visceral fat and lean mass composition were assessed using a DXA scan.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.